The HR− HER2− group showed the highest number of mutations per patient, consistent with the literature that triple‐negative breast cancer had higher tumor mutational burden than other subtypes [21, 22], making it a good candidate for immune checkpoint therapy. This evidence concerns the gene ERBB2 and neoplasm.